ZLTQ Zeltiq Aesthetics, Inc.

ZELTIQ® Aesthetics, Inc. (Nasdaq: ZLTQ), a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform, today announced CoolSculpting, its non-surgical, clinically proven procedure designed to selectively reduce fat in treated areas using a patented cooling technology, will be featured in several podium presentations and e-posters at the American Society for Laser Medicine and Surgery annual conference (ASLMS) in Boston, April 3-7, 2013. Physicians will be presenting their own data.

“Since CoolSculpting’s commercial launch in 2010, we are pleased that the medical community continues to recognize and adopt our patented cooling technology to noninvasively reduce fat,” said Mark Foley, President and CEO of ZELTIQ. “We look forward to the ongoing evolution of CoolSculpting as led by our physician partners and the growth opportunity it presents for their practices.”

For the complete ASLMS program, visit www.aslms.org. For information about CoolSculpting, visit ZELTIQ at Booth #909.

     

WHAT:

CoolSculpting

ZELTIQ Booth #909  

WHEN:

ASLMS Exhibit Hours

Friday, April 5, 2013, 9:00 a.m. – 5:00 p.m. Saturday, April 6, 2019, 9:00 a.m. – 7:30 p.m.  

WHERE:

American Society for Laser Medicine and Surgery (ASLMS) Annual Conference

Hynes Convention Center 900 Boylston Street Boston, MA 02115  

About ZELTIQ® Aesthetics, Inc.

ZELTIQ is a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform. ZELTIQ’s first commercial product, the CoolSculpting System, is designed to selectively reduce stubborn fat that may not respond to diet or exercise. CoolSculpting is based on the scientific principle that fat cells are more sensitive to cold than the overlying skin and surrounding tissues. It utilizes patented technology of precisely controlled cooling to reduce the temperature of fat cells in the treated area, which is intended to cause fat cell elimination through a natural biological process known as apoptosis, without causing scar tissue or damage to the skin, nerves, or surrounding tissues. ZELTIQ developed CoolSculpting to safely, noticeably, and measurably reduce the fat layer.

IC1318-AIn the United States CoolSculpting is cleared for non-invasive fat reduction of the abdomen and flank.